Monobactam Antibacterial Drug Class List

Drugs in Drug Class: Monobactam Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes	8,835,455		Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes	9,695,122		Y	Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes	7,612,087		Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes	8,471,025			Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes	9,284,314			Y
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes

Market Dynamics and Patent Landscape for Monobactam Antibacterial Drugs (Aztreonam, Carumonam, Others): Exclusivity, Generic Entry Risk, and Litigation Outlook

Last updated: July 22, 2026

Monobactam antibacterial demand is concentrated in aztreonam, with limited late-cycle pipeline depth and constrained combination opportunities. Patent protection is largely driven by legacy composition-of-matter and formulation/process patents around aztreonam, with the main market-exposure risk tied to how quickly FDA-controlled generic and section viii pathway filings can overcome manufacturing and substitution barriers. The competitive dynamic is dominated by (1) whether additional aztreonam bottlenecks exist in sterile manufacturing, (2) whether line extensions and new dosage forms trigger new exclusivity, and (3) whether any “new” monobactam candidates can secure enforceable coverage in the US via late-stage Orange Book listings.

Which monobactam antibacterial drugs drive the market and where is growth coming from?

Monobactams target Gram-negative bacteria with limited spectrum compared with broader beta-lactams, which makes their commercial base narrower but clinically persistent for specific use cases, especially when other classes are contraindicated.

Aztreonam: the commercial anchor

• Active ingredient: aztreonam (parenteral monobactam)
• Primary market role: treatment of serious Gram-negative infections in hospital settings, including use where beta-lactam cross-reactivity avoidance is a clinical priority.
• Revenue sensitivity: high to hospital formularies, antibiotic stewardship restrictions, and payer preference.

Carumonam and other monobactams: lower US visibility

• Carumonam: largely outside the core current US monobactam market dynamic (in practice, fewer active US-centric patent and commercial levers than aztreonam).
• Other monobactam candidates: typically earlier-stage or not sustained as a US commercial franchise, limiting the relevance of a full global patent estate analysis for market entrants.

What patents protect aztreonam monobactam antibacterials in the US?

Monobactam patent estates in the US tend to cluster around classic archetypes: composition of matter (or salt/crystal form), manufacturing/process, and sterile formulation/process controls. The enforceability and generic entry risk depend on whether any late-listed patents remain active in the Orange Book for specific NDA/Licensed products.

Patent estate building blocks typically seen for aztreonam

Holders usually secure:

• Composition of matter: aztreonam and certain pharmaceutically acceptable salts.
• Polymorph/crystal form: where patentability was supported at discovery time.
• Formulation patents: sterile lyophilized powder composition, reconstitution characteristics, stabilizers, and viscosity/reconstitution handling.
• Method-of-manufacture patents: sterile fill-finish parameters, drying/lyophilization cycles, particle size control.
• Method-of-use patents: narrower in scope due to obviousness risk post-market, but still appear for targeted indications.

Which listings matter most for generic entry

For an FDA generic challenge strategy, the practical “permission to launch” is driven by:

• The last expiring Orange Book patent applicable to the reference product’s relevant strengths and dosage forms.
• Whether remaining patents are framed as manufacturing/process claims that generics can design around versus composition claims that block entry more directly.
• Whether the manufacturer’s controls create enforceable “how it is made” barriers that prevent a commercially equivalent ANDA.

When does aztreonam lose exclusivity and what are the key expiration drivers?

Exclusivity is split between:

1. regulatory exclusivity (data exclusivity, orphan exclusivity if applicable, pediatric exclusivity)
2. patent exclusivity (Orange Book-listed patents)

Timeline mechanics that govern launch

• First generic viability: depends on the earliest patent expiration date tied to the active ingredient and dosage form of the reference product.
• Last generic viability: depends on the last-to-expire Orange Book patent for that specific NDA strength/dosage form.

Practical exposure: “late-cycle” listings

A common late-cycle risk pattern is that even when composition-of-matter expires, process and formulation patents can extend enforceable barriers for reconstituted parenterals. For monobactams, sterile manufacturing and stability claims can still be the decisive layer.

How many patents cover aztreonam formulations and manufacturing in the Orange Book?

Orange Book coverage for legacy antibiotics is often broad but not always deep. In practice, the patent count is less important than:

• whether those patents are still in force
• whether they map to the strengths/dosage forms the generic intends to market
• whether any are listed for specific packaging configurations

What to expect in patent grouping

For aztreonam, the remaining Orange Book filings (when they exist) typically group into:

• formulation and stability
• sterile fill-finish
• manufacturing process parameters
• sometimes a narrow method-of-use

Launch-relevant categories to track

For diligence, focus on:

• drug substance/manufacturing
• drug product/manufacturing
• sterile presentation and reconstitution
• stability and shelf-life

What formulations are protected by monobactam patent estates?

Formulation protection often aims at:

• stabilizing aztreonam under storage and reconstitution conditions
• controlling particle size distribution and moisture uptake for lyophilized products
• ensuring compatibility and performance in infusion workflows

Sterile parenteral formulation bottlenecks

Key formulation levers that can create generic launch resistance:

• lyophilization cycle control tied to residual moisture and cake structure
• stabilizers that preserve assay and degradation profile
• reconstitution time and concentration targets that support use in clinical settings

Reformulation as a patent-risk lever

If any reference product introduces:

• new strength
• new delivery configuration
• new reconstitution method the patent holder can capture additional Orange Book listings. This creates delayed entry even when the “core API” patent is already gone.

What generic entry risks exist for aztreonam and other monobactams?

Generic entry risks are highest where at least one of the following is true:

• an Orange Book-listed patent still covers the specific dosage form
• the remaining patents are process claims that are hard to design around without losing bioequivalence metrics
• there is evidence of Paragraph IV filings that led to settlement delay

ANDA substitution friction

For hospital antibacterials, substitution friction can slow generic uptake even after legal entry, due to:

• formulary inertia
• procurement contract structures
• stewardship preference for known stability/performance characteristics

Which companies are challenging monobactam patents with Paragraph IV certifications?

Paragraph IV challenges are the primary window into:

• which patents the market believes are still enforceable
• which patents are likely to be waived/held invalid
• which settlement structures are being used to delay launch

Typical challenge pattern for legacy antibiotics

• multiple ANDA filers test the boundary of the last-to-expire Orange Book layer
• settlements often structure launch dates by product and strength
• court outcomes are less frequent than settlement-based resolution in mature antibiotic franchises

What patent litigation affects monobactam antibacterials?

Patent litigation risk is concentrated around:

• scope of composition/formulation claims
• whether the generic’s manufacturing process avoids infringement
• whether asserted patents are valid and enforceable

What to track in monobactam litigation

• case filing date versus Orange Book status
• whether the dispute concerns the method-of-use layer or the manufacturing/process layer
• whether a final judgment or a settlement controls the launch

Settlement-driven timelines

For mature antibiotics, settlements often produce:

• delayed launch (fixed dates)
• covenants not to sue tied to design-around efforts
• product carve-outs by strength or packaging

What is the Orange Book status of aztreonam products?

Orange Book status determines whether generics can lawfully file and when they can launch. For diligence, the controlling fields are:

• NDA number
• drug substance and dosage form
• Orange Book patent list
• expiration date by patent
• listed exclusivities (if any) associated with the NDA

Decision rule for generic viability

A generic’s launch eligibility hinges on:

• the last expiring relevant Orange Book patent
• whether a court injunction or settlement agreement bars launch beyond expiration

How strong is the patent estate for monobactam antibacterials?

Patent strength for this class is best assessed by layering:

• breadth of claim scope (composition vs narrow process)
• remaining term (how many years and months are left)
• litigation track record and whether settlements are common for this reference product
• whether generics have already entered successfully (a proxy for whether patents are meaningfully enforced)

Strength tends to be concentrated

For legacy monobactams:

• the earliest-expiring core chemistry patents may be fully exhausted
• the “survivors” are usually formulation/process, which are narrower but can still block entry if claim scope covers the generic design

How does aztreonam compare with other monobactams on patent and commercial dynamics?

Clinical positioning differences

• aztreonam dominates commercialization in practice.
• non-aztreonam monobactams have weaker US commercialization footprints, which limits the scale of enforceable US patent estates tied to current sales.

Patent estate differences

• aztreonam: large legacy estate with multiple layers over time.
• other monobactams: smaller footprints and less consistent Orange Book presence.

What manufacturing and IP barriers block generic monobactam supply?

Generic feasibility is often constrained by:

• sterile manufacturing controls
• lyophilized product process replication
• stability targets under real-world distribution conditions

Sterile fill-finish and process control claims

Even if composition claims expire, manufacturing/process claims can impede entry if:

• claim language covers parameters that the generic cannot avoid
• infringement hinges on process characterization that is tightly linked to stability performance

How do biosimilars apply to monobactam antibacterials?

Monobactams are small-molecule antibacterials, so biosimilar pathways do not apply. The generic pathway is ANDA for small molecules and not a biologics license pathway.

Revenue exposure and what timing matters for investors and licensors

Revenue exposure is driven by:

• how much spend is concentrated in the aztreonam formulary category
• the number of competing products that can substitute after generic entry
• the remaining enforceable patent term and whether any settlements create additional delay

Timing checkpoints for decision-making

• next Orange Book patent expiration date for relevant strengths
• any scheduled court events in ongoing ANDA suits
• settlement “launch date” milestones (if applicable)

What licensing and deal structures typically arise in monobactam antibacterial exclusivity?

When exclusivity is near-term or when process/formulation patents remain in force, deals tend to follow:

• settlement-based licensing agreements allowing early-to-midterm commercial launch under defined scope
• territorial or strength-limited licensing
• manufacturing site-specific arrangements to reduce design-around disputes

Commercial rationale

• holders can monetize remaining term without prolonged litigation cost
• challengers can reduce uncertainty and shorten time to market

Key Takeaways

• Monobactam antibacterial market dynamics are anchored by aztreonam; growth and risk concentrate in sterile parenteral execution and formulary acceptance rather than spectrum expansion.
• Patent protection in monobactams is most likely to persist through formulation and manufacturing/process patents once core composition-of-matter expires.
• Generic entry risk is determined by the last-to-expire Orange Book patent for the specific NDA strength/dosage form, plus whether remaining patents are difficult to design around.
• Litigation and settlements shape practical launch timing more than adjudicated outcomes in many legacy antibiotic franchises.
• Biosimilar risk does not apply; competition is ANDA-driven.

FAQs

1) What are the most common monobactam antibacterial patent claim types that block ANDA launches?

Formulation/stability and sterile manufacturing process claims tied to lyophilization and reconstitution performance are most often relevant for design-around barriers after composition-of-matter expiration.

2) Do monobactam patents typically extend beyond composition-of-matter expiration?

Yes, when formulation, stability, or process patents remain in force for the specific dosage form and strength listed in the Orange Book.

3) How do hospital formulary dynamics affect generic uptake after legal entry for aztreonam?

Even after patent expiry, procurement contracts, antibiotic stewardship preferences, and known reconstitution/performance profiles can delay switching.

4) What is the fastest pathway to market after Orange Book patent expiration for small-molecule monobactams?

A generic can launch once it satisfies the legal status tied to the last relevant Orange Book patent and any court injunction or settlement terms.

5) Are monobactam antibacterials vulnerable to additional patent extensions through new formulations?

If new strengths, dosage forms, or reformulation initiatives trigger new Orange Book listings with valid patents, they can delay generic entry for those specific SKUs.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). Drug Applications and Databases: ANDA, Paragraph IV certifications. U.S. Food and Drug Administration.